首頁 > 市場調查報告書 > 製藥

臨床實驗

市場調查報告書

商品編碼

1707354

全球 NPHP5 視網膜變性治療市場（按治療類型、適應症、分銷管道和地區分類）

Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, By Indication, By Distribution Channel, By Geography

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球 NPHP5 視網膜變性治療市場規模估計為 1,580 萬美元，預計到 2032 年將達到 1.333 億美元，2025 年至 2032 年的複合年成長率為 35.6%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	1580萬美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	35.60%	2032年價值預測	1.333億美元

數字。 2025年NPHP5視網膜變性治療全球市場佔有率（%）

NPHP5 視網膜變性，也稱為 Senior-Loken 症候群 7，是一種罕見的遺傳性纖毛疾病，會導致進行性視力障礙，並可能導致完全失明。該疾病是由 NPHP5 基因突變引起的，該基因編碼腎囊素-5，這是對纖毛功能很重要的蛋白質。此疾病的特徵是視網膜色素變性、腎病變和其他全身性病變。目前，尚無針對 NPHP5 視網膜退化的核准治療方法，治療包括低視力輔助和支持性護理。然而，最近對發病機制的研究揭示了潛在的藥物標靶，例如纖毛功能，這為治療開闢了新的途徑。幾家生物製藥公司已經啟動臨床試驗，評估基因療法和其他新型治療方法，以恢復這些患者的視力。 Senior-Loken（SL）是一種體染色體隱性遺傳症候群，是腎病變相關疾病的變體，其中囊性腎病變伴隨視網膜營養不良（視網膜色素變性或萊伯氏先天性黑朦症）。這是一種毀滅性的疾病，可能導致失明和腎衰竭。

市場動態：

NPHP5 視網膜變性治療市場受到對這種衰弱性疾病的有效治療的未滿足醫療需求的推動。據估計，全球整體每 20 萬名新生兒中就有 1 名患有 NPHP5 視網膜退化。纖毛通路研究的不斷增加以及視網膜基因治療的最新突破正在擴大治療機會，進一步推動市場成長。然而，將基因輸送到眼睛的技術挑戰和罕見疾病藥物的高開發成本繼續限制市場收益。同時，生物技術公司和研究機構之間的合作，以及對罕見疾病和研發的公共和私人資金的增加，為市場進入者創造了有利可圖的機會。

本研究的主要特點

本報告對全球 NPHP5 視網膜變性治療市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率(CAGR)。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
該報告根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球 NPHP5 視網膜變性治療市場的領導者。研究涉及的主要公司包括 ProQR Therapeutics、Editas Medicine、Nanoscope Therapeutics、jCyte、Biogen、Novartis AG、Spark Therapeutics、MeiraGTx、NightstaRx、Beacon Therapeutics、Applied Genetic Technologies Corporation、ViGeneron 和 RetinAI Medical。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球 NPHP5 視網膜變性治療市場報告涉及該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過用於分析全球 NPHP5 視網膜變性治療市場的各種策略矩陣來做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 15.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	35.60%	2032 Value Projection:	USD 133.3 Mn

NPHP5 retinal degeneration, also known as Senior-Loken syndrome 7, is a rare genetic ciliopathy that causes progressive visual impairment and can lead to complete blindness. It is caused by mutations in the NPHP5 gene, which encodes for nephrocystin-5, a protein critical for cilia function. The condition is characterized by retinitis pigmentosa, nephronophthisis, and other systemic involvement. Currently, there is no approved treatment for NPHP5 retinal degeneration, and management involves low vision aids and supportive care. However, recent research investigating the pathogenic mechanisms has uncovered potential drug targets such as cilia function, which is opening up new avenues for treatment development. Several biopharmaceutical companies have started clinical trials evaluating gene therapy and other novel therapeutic approaches to restore vision in these patients. Senior-Loken (S-L) is an autosomal recessive syndrome and a variant of the nephronophthisis-associated disorders, in which the cystic kidney disease is associated with retinal dystrophy (retinitis pigmentosa or Leber congenital amaurosis). It is a deleterious disease that culminates in blindness and renal failure.

Market Dynamics:

The NPHP5 retinal degeneration treatment market is driven by the high unmet medical need for an effective treatment for this debilitating condition. As per estimates, NPHP5 retinal degeneration has a prevalence of 1 in 200,000 live births globally. The increasing research focus on cilia pathways and recent breakthroughs in retinal gene therapy are further boosting market growth by expanding therapeutic opportunities. However, technical challenges associated with ocular gene delivery and the high costs of developing orphan disease therapies continue to restrain market revenues. On the other hand, partnerships between biotech firms and research institutions, growing public-private funding for rare disease, research and development present lucrative opportunities for market players.

Key features of the study:

This report provides in-depth analysis of the global NPHP5 retinal degeneration treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global NPHP5 retinal degeneration treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include ProQR Therapeutics, Editas Medicine, Nanoscope Therapeutics, Inc., jCyte, Inc., Biogen, Novartis AG, Spark Therapeutics, MeiraGTx, NightstaRx, Beacon Therapeutics, Applied Genetic Technologies Corporation, ViGeneron and RetinAI Medical
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global NPHP5 retinal degeneration treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global NPHP5 retinal degeneration treatment market

Detailed Segmentation:

Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type
- Gene Therapy
- Cell Therapy
- Drug Therapy
- Others
Global NPHP5 Retinal Degeneration Treatment Market, By Indication
- Retinitis Pigmentosa
- Leber Congenital Amaurosis
- Usher Syndrome
- Others
Global NPHP5 Retinal Degeneration Treatment Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global NPHP5 Retinal Degeneration Treatment Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- ProQR Therapeutics
- Editas Medicine
- Nanoscope Therapeutics, Inc.
- jCyte, Inc.
- Biogen
- Novartis AG
- Spark Therapeutics
- MeiraGTx
- NightstaRx
- Beacon Therapeutics
- Applied Genetic Technologies Corporation
- ViGeneron
- RetinAI Medical

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing Launch of Awareness Campaigns
- Long approval timelines
- Emerging markets in Asia Pacific and Latin America
Key Highlights
Regulatory Scenario
Market Trends
PEST Analysis
PORTER's Analysis
Product Launches
Epidemiology
Mergers, Acquisitions, and Collaborations

4. Global NPHP5 Retinal Degeneration Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Drug Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global NPHP5 Retinal Degeneration Treatment Market, By Indication, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Retinitis Pigmentosa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Leber Congenital Amaurosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Usher Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global NPHP5 Retinal Degeneration Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global NPHP5 Retinal Degeneration Treatment Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profile
- ProQR Therapeutics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Editas Medicine
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Nanoscope Therapeutics, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- jCyte, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Biogen
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Novartis AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Spark Therapeutics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- MeiraGTx
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- NightstaRx
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Beacon Therapeutics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Applied Genetic Technologies Corporation
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- ViGeneron
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- RetinAI Medical
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

10. Section

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

全球 NPHP5 視網膜變性治療市場（按治療類型、適應症、分銷管道和地區分類）

Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, By Indication, By Distribution Channel, By Geography

市場動態：

本研究的主要特點

目錄

第1章調查目的與前提條件

第2章市場展望

第3章市場動態、法規與趨勢分析

4.全球NPHP5 視網膜退化治療市場-冠狀病毒 (COVID-19) 大流行的影響

5. 2020 年至 2032 年全球 NPHP5 視網膜退化治療市場（依治療類型）

6.全球NPHP5 視網膜退化治療市場（依適應症分類），2020 年至 2032 年

7. 2020 年至 2032 年全球 NPHP5 視網膜退化治療市場（依分銷管道）

8.全球NPHP5 視網膜變性治療市場（按地區），2020 年至 2032 年

第9章競爭態勢

第 10 章章節

Market Dynamics:

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global NPHP5 Retinal Degeneration Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)

6. Global NPHP5 Retinal Degeneration Treatment Market, By Indication, 2020-2032, (US$ Mn)

7. Global NPHP5 Retinal Degeneration Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)

8. Global NPHP5 Retinal Degeneration Treatment Market, By Region, 2020-2032, (US$ Mn)

9. Competitive Landscape

10. Section

全球 NPHP5 視網膜變性治療市場（按治療類型、適應症、分銷管道和地區分類）

Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, By Indication, By Distribution Channel, By Geography

市場動態：

本研究的主要特點

目錄

第1章 調查目的與前提條件

第2章 市場展望

第3章市場動態、法規與趨勢分析

4.全球NPHP5 視網膜退化治療市場-冠狀病毒 (COVID-19) 大流行的影響

5. 2020 年至 2032 年全球 NPHP5 視網膜退化治療市場（依治療類型）

6.全球NPHP5 視網膜退化治療市場（依適應症分類），2020 年至 2032 年

7. 2020 年至 2032 年全球 NPHP5 視網膜退化治療市場（依分銷管道）

8.全球NPHP5 視網膜變性治療市場（按地區），2020 年至 2032 年

第9章 競爭態勢

第 10 章 章節

Market Dynamics:

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global NPHP5 Retinal Degeneration Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)

6. Global NPHP5 Retinal Degeneration Treatment Market, By Indication, 2020-2032, (US$ Mn)

7. Global NPHP5 Retinal Degeneration Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)

8. Global NPHP5 Retinal Degeneration Treatment Market, By Region, 2020-2032, (US$ Mn)

9. Competitive Landscape

10. Section

第1章調查目的與前提條件

第2章市場展望

第9章競爭態勢

第 10 章章節